Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types.

An unpaired Student's t -test demonstrated that both combination treatments were significantly different to the appropriate controls, which resulted in an overall highly significant one-way ANOVA test ( P <0.00001).

also in 132,142 other papers